2nd Quarter - Report

ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Signed a Protecting Access to Pain Relief (PAPR) Coalition letter urging HHS to explore and support new efforts and support new efforts to promote the work and recommendations of the HHS Pain Management Best Practices Inter-Agency Task Force. Signed letter in support of H.R. 8920, the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern Rep. Ed Perlmutter
MICHAEL WARD New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 8920 (117th)

Medicare/Medicaid MMM

Signed a letter in support of the CONNECT for Health Act 2021 (S.1512) Signed a letter in support of the Comprehensive Care for Alzheimers Act (S. 1125/H.R. 2517) Signed a letter from the Medical Imaging and Technology Alliance (MITA) urging the Coverage and Analysis Group within CMS to open the pending reconsideration request for amyloid Positron Emission Tomography (PET) scans. Signed letter urging the House of Representatives and the Senate to create an out-of-pocket cap in Medicare Part D, reform the Part D exceptions and appeals process, bolster the low-income subsidy program, eliminate cost-sharing for Part D vaccines, and improve information and consumer education for Part D beneficiaries. Signed a letter as part of the Psychoactive Appropriate Use for Safety and Effectiveness (Project PAUSE) urging CMS to revise the measures of inappropriate use of antipsychotics in skilled nursing facilities and enhance the documentation to support CMSs ability to assess and investigate inappropriate prescribing practices Submitted letter to Congressional leadership urging an annual out-of-pocket cap in Part D; expansion of low-income subsidy eligibility; placing an inflationary cap in Part D; a requirement that Part D plans share a portion of sales of rebates with beneficiaries at the point of sale; strengthen the Part D appeals process; expand Medicare coverage for dental, vision, and hearing services; and not include the quality-adjusted life year metric in any drug pricing legislation. Sent letter to House of Representatives leadership urging them not to include International Reference Pricing and Quality-Adjust Life Year metrics in drug pricing legislation. Met virtually with the House of Representatives and Senate to discuss creating an annual out-of-pocket cap in Medicare Part D, creating a smoothing proposal, and warning against the use of quality-adjusted life-year metrics to determine drug value.

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern Rep. Ed Perlmutter
MICHAEL WARD New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1125 (117th), H.R. 2517 (117th), S. 1512 (117th)

Budget/Appropriations BUD

Submitted letter to the Senate Appropriations Subcommittee on Military Construction, Veterans Affairs, and Related Agencies to support at least $902 million in the Fiscal Year (F.Y.) 2022 appropriation for the Department of Veterans Affairs (V.A.) Medical and Prosthetic Research program. Signed letter to House and Senate appropriations subcommittees urging a $289 million increase for National Institutes of Health (NIH) research on Alzheimers disease and other forms of dementia to accelerate progress as articulated in the Bypass Budget Proposal for FY22; a $500 million increase for aging research across the NIH, in addition to the funding for dementia-specific research, to ensure that the NIH has the resources to address the many other age-related chronic diseases that affect people with dementia; a $3.2 billion increase for the NIHs current institutes and operations, including funds from the 21st Century Cures Act for targeted initiatives; $6.5 billion to launch the Advanced Research Projects Agency for Health (ARPA-H); $560 million for the BRAIN Initiative; $200 million for the FDA, in addition to funds included in the 21st Century Cures Act for targeted initiatives double funding for Older Americans Act programs and services; a $7.5 million increase for the ACL Alzheimers Disease Program; an $8.263 million increase for the HRSA geriatrics workforce programs; a $2 million increase for the DoJ Missing Alzheimers Disease Alert Program; $60 million for the CDCs Alzheimers Disease and Healthy Aging Program (ADHAP) to continue BOLD Act implementation, expand the CDC Healthy Brain Initiative road map for state and national partnerships, and reduce dementia risk through brain health promotion; and a $500 million increase for the Federally Qualified Health Centers (FQHCs).

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern, Rep. Ed Perlmutter
MICHAEL WARD —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Signed Ad Hoc Group for Medical Research letter urging investments in medical research be included in any future legislative package focused on bolstering infrastructure. Further, the letter recommended that Congress pass the RISE Act (H.R. 869/S.289) Signed letter supporting the continued use of human fetal tissue in federal biomedical research

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern. Rep. Ed Perlmutter
MICHAEL WARD —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 869 (117th), S. 289 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.